These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Comment: Persistence of Mycobacterium leprae in the peripheral nerves of multidrug-treated leprosy patients. Grange JM; Beck JS; Abbot NC Lepr Rev; 1993 Sep; 64(3):280. PubMed ID: 8110236 [No Abstract] [Full Text] [Related]
4. Prospects for chemotherapy of leprosy. Ji B Indian J Lepr; 2000; 72(2):187-98. PubMed ID: 11008659 [No Abstract] [Full Text] [Related]
5. [How should leprosy be treated?]. Mahé A Ann Dermatol Venereol; 1998 Dec; 125(12):881-3. PubMed ID: 9922859 [No Abstract] [Full Text] [Related]
6. WHO global strategy for further reducing the leprosy burden and sustaining leprosy control activities (Plan period: 2006-2010). World Health Organization Indian J Lepr; 2006; 78(1):7-31. PubMed ID: 16646281 [No Abstract] [Full Text] [Related]
7. Antileprotic effect of the immunostimulating drug RACA 854 in experimentally infected armadillos. Kazda J; Shafik A Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):649-51. PubMed ID: 1802947 [No Abstract] [Full Text] [Related]
8. Chemotherapy of the mycobacterial diseases--leprosy and tuberculosis. Krenzien HN Indian J Chest Dis Allied Sci; 1982; 24(2-3):223-32. PubMed ID: 6762341 [No Abstract] [Full Text] [Related]
9. National Leprosy Eradication Programme, India. National Action Plan for 2006-07. Central Leprosy Division of the Directorate General of Health Services Indian J Lepr; 2006; 78(1):48-50. PubMed ID: 16646283 [No Abstract] [Full Text] [Related]
10. WHO regional strategy for sustaining leprosy services and further reducing the burden of leprosy, 2006-2010. WHO Regional Office for South-East Asia Indian J Lepr; 2006; 78(1):33-47. PubMed ID: 16646282 [No Abstract] [Full Text] [Related]
11. [New WHO recommendations for the treatment of leprosy]. Acta Leprol; 1997; 10(4):189. PubMed ID: 9527754 [No Abstract] [Full Text] [Related]
12. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice. Dhople AM; Ibanez MA Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013 [TBL] [Abstract][Full Text] [Related]
13. Leprosy at a turning point? Harboe M Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):312-8. PubMed ID: 11221095 [No Abstract] [Full Text] [Related]
14. A plea to revive skin smear examination. Porichha D Int J Lepr Other Mycobact Dis; 2001 Jun; 69(2):116-9. PubMed ID: 11757169 [No Abstract] [Full Text] [Related]
15. Single dose ROM therapy in Goa. Shukla P; Miranda MS; Prabhudesai R; Rege VL Indian J Lepr; 2002; 74(2):169-72. PubMed ID: 12708738 [No Abstract] [Full Text] [Related]
16. A overview of ocular leprosy after 2 decades of multidrug therapy. Lewallen S; Courtright P Int Ophthalmol Clin; 2007; 47(3):87-101. PubMed ID: 17667278 [No Abstract] [Full Text] [Related]
19. [Morphologic characteristics of leproma cell cultures from humans and experimental animals and the effect on them of antileprotic preparations]. Vishnevetsiĭ FE; Iushchenko AA; Anokhina VV Biull Eksp Biol Med; 1988 Dec; 106(12):737-41. PubMed ID: 3207885 [TBL] [Abstract][Full Text] [Related]
20. Single-dose treatment for paucibacillary leprosy; feasibility of long-term follow up. Ganapati R; Revankar CR; Pai VV; Kingsley S Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):308-9. PubMed ID: 10575413 [No Abstract] [Full Text] [Related] [Next] [New Search]